Emerging Therapies for the Myelodysplastic Syndromes

Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge. Considerable barriers to timely development of effective therapy include the dive...

Full description

Saved in:
Bibliographic Details
Published inClinical hematology international Vol. 2; no. 1; pp. 13 - 17
Main Author Canaani, Jonathan
Format Journal Article
LanguageEnglish
Published Dordrecht Springer Netherlands 01.03.2020
Atlantis Press
SAABRON PRESS
Subjects
Myelodysplastic syndromes
Review
Review Article
Myelodysplastic syndromes
Online AccessGet full text

Cover

More Information
Summary:Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge. Considerable barriers to timely development of effective therapy include the diverse molecular landscape encountered in MDS patients, the difficulty in translating specific molecular aberration into a clinically meaningful animal model, as well as challenges in patient recruitment into clinical trials. These speak to the need to discover efficacious novel therapeutic targets which would in turn translate into improved patient outcomes in terms of both survival and quality of life. In this review, we outline recently published data pertaining to therapeutic advances in TGF- β pathway inhibition, STAT3, Hedgehog signaling, and additional therapeutic venues being actively explored in MDS.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2590-0048
2590-0048
DOI:10.2991/chi.d.191202.001